| Phase 12 trials |
|
Phase 1
|
NCT05675202 |
Jan → Aug 2023 |
chronic kidney disease |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03510767 |
Jun 2018 → Aug 2022 |
lymphoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT05284994 |
Mar 2022 → Apr 2024 |
non-small cell lung carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT04808570 |
Jun 2021 → Nov 2023 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT04690725 |
Oct 2020 → Jan 2022 |
— |
Peking University People's Hospital |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT04355520 |
Jul 2020 → Jun 2021 |
hormone receptor-positive breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT04836663 |
Apr 2021 → Sep 2022 |
cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04610970 |
Jan 2021 → Mar 2022 |
diffuse large B-cell lymphoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04615468 |
Dec 2020 → Oct 2021 |
peripheral T-cell lymphoma, not otherwise specified |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04398953 |
Jul 2020 → Sep 2021 |
mantle cell lymphoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04324879 |
May 2020 → Dec 2022 |
B-cell neoplasm |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|